We conclude that further development studies with 135H12, possibly optimization steps to further increase its affinity for EphA2 ligand binding domain, could translate these findings into novel and effective anti-metastatic therapeutics agents for prostate cancer and possibly other indications, including pancreatic and breast cancer. Here, EPHA2 is linked to breast cancer.